NasdaqGS:NRC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. More Details


Snowflake Analysis

Solid track record with adequate balance sheet.

Share Price & News

How has National Research's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NRC is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: NRC's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-3.0%

NRC

0.1%

US Healthcare

2.1%

US Market


1 Year Return

-16.3%

NRC

12.1%

US Healthcare

19.8%

US Market

Return vs Industry: NRC underperformed the US Healthcare industry which returned 12% over the past year.

Return vs Market: NRC underperformed the US Market which returned 19.7% over the past year.


Shareholder returns

NRCIndustryMarket
7 Day-3.0%0.1%2.1%
30 Day3.2%5.8%8.1%
90 Day-6.4%8.3%6.0%
1 Year-15.6%-16.3%13.6%12.1%22.5%19.8%
3 Year66.0%57.4%32.4%27.0%46.5%36.8%
5 Year294.6%252.3%77.6%65.0%96.9%75.3%

Long-Term Price Volatility Vs. Market

How volatile is National Research's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is National Research undervalued compared to its fair value and its price relative to the market?

35.55x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: NRC ($53.45) is trading above our estimate of fair value ($17.31)

Significantly Below Fair Value: NRC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: NRC is poor value based on its PE Ratio (35.5x) compared to the US Healthcare industry average (23.9x).

PE vs Market: NRC is poor value based on its PE Ratio (35.5x) compared to the US market (19.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NRC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NRC is overvalued based on its PB Ratio (23.8x) compared to the US Healthcare industry average (3.2x).


Next Steps

Future Growth

How is National Research forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as National Research has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has National Research performed over the past 5 years?

16.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NRC has high quality earnings.

Growing Profit Margin: NRC's current net profit margins (28.7%) are higher than last year (24.9%).


Past Earnings Growth Analysis

Earnings Trend: NRC's earnings have grown by 16% per year over the past 5 years.

Accelerating Growth: NRC's earnings growth over the past year (19.9%) exceeds its 5-year average (16% per year).

Earnings vs Industry: NRC earnings growth over the past year (19.9%) underperformed the Healthcare industry 22.6%.


Return on Equity

High ROE: NRC's Return on Equity (66.5%) is considered outstanding.


Next Steps

Financial Health

How is National Research's financial position?


Financial Position Analysis

Short Term Liabilities: NRC's short term assets ($47.4M) exceed its short term liabilities ($32.1M).

Long Term Liabilities: NRC's short term assets ($47.4M) exceed its long term liabilities ($38.4M).


Debt to Equity History and Analysis

Debt Level: NRC's debt to equity ratio (55.7%) is considered high.

Reducing Debt: NRC's debt to equity ratio has increased from 7.1% to 55.7% over the past 5 years.

Debt Coverage: NRC's debt is well covered by operating cash flow (115.1%).

Interest Coverage: NRC's interest payments on its debt are well covered by EBIT (22.9x coverage).


Balance Sheet


Next Steps

Dividend

What is National Research current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NRC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NRC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NRC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NRC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: NRC is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NRC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

14.0yrs

Average board tenure


CEO

Mike Hays (65 yo)

39.83yrs

Tenure

US$233,878

Compensation

Mr. Michael D. Hays, also known as Mike, serves as an Advisor of Picker Institute Inc. Mr. Hays founded National Research Corp. in 1981 and has been its Chief Executive Officer since 1981 and serves as its...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD233.88K) is below average for companies of similar size in the US market ($USD4.15M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Michael Hays
Founder39.83yrsUS$233.88k26.13%
$ 352.8m
John Nunnelly
Lead Independent Director8.5yrsUS$175.00k0.11%
$ 1.4m
JoAnn Martin
Independent Director19.42yrsUS$150.00k1.23%
$ 16.7m
Donald Berwick
Independent Director5.08yrsUS$150.00kno data

14.0yrs

Average Tenure

66yo

Average Age

Experienced Board: NRC's board of directors are seasoned and experienced ( 14 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: NRC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

National Research Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: National Research Corporation
  • Ticker: NRC
  • Exchange: NasdaqGS
  • Founded: 1981
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.350b
  • Shares outstanding: 25.26m
  • Website: https://nrchealth.com

Number of Employees


Location

  • National Research Corporation
  • 1245 Q Street
  • Lincoln
  • Nebraska
  • 68508
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NRCNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2013
NR1ABST (Boerse-Stuttgart)YesCommon StockDEEURMay 2013

Biography

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscripti...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 23:03
End of Day Share Price2020/11/25 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.